Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer

Cancer Prevention Research

Volumn 7, Issue 7, 2014, Pages 686-697

  Bruegl, Amanda S ^a   Djordjevic, Bojana ^b   Batte, Brittany ^a   Daniels, Molly ^a   Fellman, Bryan ^a   Urbauer, Diana ^a   Luthra, Rajyalakshmi ^a   Sun, Charlotte ^a   Lu, Karen H ^a   Broaddus, Russell R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN; PROTEIN MLH1; ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ENDOMETRIUM CARCINOMA; FAMILY HISTORY; FEMALE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHYLATION; MISMATCH REPAIR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; TUMOR LOCALIZATION; ADOLESCENT; AGED; CANCER GRADING; CANCER STAGING; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPLICATION; DNA METHYLATION; ECONOMICS; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; EVALUATION STUDY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84904308214     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0359     Document Type: Article

References (44)

1. Backes FJ, Cohn DE. Lynch syndrome. Clin Obstet Gynecol 2011;54: 199-214.
2. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005; 105:569-74. (Pubitemid 40271224)
3. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009;137:1621-7.
4. Lynch HT, Harris RE, Lynch PM, Guirgis HA, Lynch JF, Bardawil WA. Role of heredity in multiple primary cancer. Cancer 1977;40(4 Suppl):1849-54. (Pubitemid 8216956)
5. Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354:2751-63. (Pubitemid 43974193)
6. Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006;296:1479 -87.
7. Kastrinos F, Steyerberg EW, Mercado R, Balmana J, Holter S, Gallinger S, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011;140:73-81.
8. Mercado RC, Hampel H, Kastrinos F, Steyerberg E, Balmana J, Stoffel E, et al. Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med 2012;14:670-80.
9. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107:159-62. (Pubitemid 47575743)
10. Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer 2012;118:681-8.
11. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008;10:293-300. (Pubitemid 352019113)
12. Berg AO, Armstrong K, Botkin J, Calonge N, Haddow J, Hayes M, et al. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
13. Hampel H. Genetic testing for hereditary colorectal cancer. Surg Oncol Clin N Am 2009;18:687-703.
14. Duong LM, Wilson RJ, Ajani UA, Singh SD, Eheman CR. Trends in endometrial cancer incidence rates in the United States, 1999-2006. J Womens Health 2011;20:1157-63.
15. Bartley AN, Luthra R, Saraiya DS, Urbauer DL, Broaddus RR. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res 2012;5:320-7.
16. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999;8:661-6. (Pubitemid 29139981)
17. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-60.
18. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-linePMS2 mutations. Gastroenterology 2008;135:419-28.
19. Services CfMaM. Physician fee schedule available at: http://www.cms.gov/ apps/physician-fee-schedule/search/search-criteria.aspx, 2012;
20. Laboratory fee schedule available at: http://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html, 2012.
21. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 2008;26:5965-71.
22. Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, et al. Prospective determination of prevalence of lynch syndrome in youngwomenwith endometrial cancer. J Clin Oncol 2007;25:5158-64. (Pubitemid 350232246)
23. McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K, et al. Body mass index: relationship to clinical, pathologic, and features of microsatellite instability in endometrial cancer. Gynecol Oncol 2007;104:535-9. (Pubitemid 46240240)
24. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol 2005;99:388- 92.
25. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004;127:17-25. (Pubitemid 38962270)
26. Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, et al. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 2004;74:1262-9.
27. Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999;59:5068-74. (Pubitemid 29503960)
28. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65.
29. Warthin AS. Heredity with reference to carcinoma - as shown by the study of the cases examined in the Pathological Laboratory of the University of Michigan, 1895-1913. Arch Intern Med 1913;12:546-55.
30. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305: 2304-10.
31. Chen J, Etzel CJ, Amos CI, Zhang Q, Viscofsky N, Lindor NM, et al. Genetic variants in the cell-cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. Cancer Causes Control 2009;20:1769- 77.
32. Walsh MD, Cummings MC, Buchanan DD, Dambacher WM, Arnold S, McKeone D, et al. Molecular, pathologic, and clinical features of earlyonset endometrial cancer: identifying presumptive Lynch syndrome patients. Clin Cancer Res 2008;14:1692-700. (Pubitemid 351469453)
33. Backes FJ, Leon ME, Ivanov I, Suarez A, Frankel WL, Hampel H, et al. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecol Oncol 2009;114: 486-90.
34. Leenen CH, van Lier MG, van Doorn HC, van Leerdam ME, Kooi SG, de Waard J, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer
35. Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, Zapater P, Castillejo A, Barbera VM, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology 2013;144: 926-32.
36. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011;29:2247-52.
37. Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res 2011; 4:9-22.
38. Kuismanen SA, Moisio AL, Schweizer P, Truninger K, Salovaara R, Arola J, et al. Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 2002;160:1953-8. (Pubitemid 34663387)
39. Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, van Der Zee AG, et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 1999;65:1291-8. (Pubitemid 30460379)
40. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66: 7810-7. (Pubitemid 44289242)
41. Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK, Soslow RA, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 2009;33:1639-45.
42. Grover S, Stoffel EM, Bussone L, Tschoegl E, Syngal S. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2004;2:813-9. (Pubitemid 39200720)
43. Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 2010;115: 945-52.
44. Backes FJ, Mitchell E, Hampel H, Cohn DE. Endometrial cancer patients and compliance with genetic counseling: room for improvement. Gynecol Oncol 2011;123:532-6.